Nihar R. Desai, MD, MPH

Learn how uACR and eGFR tracking, EHR prompts, and team-based titration streamline early CKD care and reduce cardiovascular risk.

See how UACR trends motivate patients, guide shared decisions, and tailor therapies to slow CKD while lowering cardiovascular risk.

Heart failure playbook reshapes CKD care: early combo therapies, right dosing, and smart uACR/eGFR follow-up to boost adherence.

Explore the four-pillars approach to slowing kidney disease—max dose ACE/ARB, add SGLT2, MRA, GLP‑1—plus access and team-based tips.

Learn how KDIGO risk staging and urine ACR guide CKD management, triage, and timely nephrology referral when red flags appear.

Clinicians rethink cardio-renal care: educate teams, streamline workflows, expand screening via pharmacists and EHRs, and prioritize prevention over dialysis.

Why uACR urine testing lags: incentives, workflow gaps, and silos—and how KDIGO staging strengthens kidney and cardiovascular risk conversations.

Learn why pairing eGFR with urine albumin-creatinine ratio improves CKD screening, avoids missed diagnoses, and guides follow-up care.

Learn how UACR testing complements eGFR, reveals hidden kidney and cardiovascular risk, and uses a color-coded heat map to guide patient communication and referrals.

Clinicians across specialties share responsibility for early kidney disease screening—use UACR and eGFR at every touchpoint to prevent patients slipping through cracks.

Why CKD screening lags despite aligned KDIGO, ADA and hypertension guidance—use eGFR plus UACR staging and EHR prompts to act earlier.

CKD guidelines agree: use eGFR plus UACR for KDIGO staging, but screening lags—see how teams and EHRs close the gap.

Experts explain how uACR and eGFR testing reveals hidden CKD, links to heart risk, and guides early, patient-centered care.

Learn how uACR and eGFR uncover hidden CKD, sharpen cardiovascular risk, and guide patient-friendly conversations for earlier, smarter care.

Desai discusses his recent observational cohort study indicating finerenone’s substantial reduction of heart failure exacerbation risk in patients with HFpEF.

This segment looks ahead to remaining challenges in FCS diagnosis and access, and to the broader implications of APOC3 inhibition for hypertriglyceridemia management.

This segment emphasizes the clinical and quality‑of‑life value of achieving deep triglyceride reductions, particularly below 500 mg/dL, in FCS.

This segment addresses practical considerations in choosing between newly approved APOC3 inhibitors for patients with FCS.

This segment explores the mechanisms of APOC3‑targeting agents and compares the triglyceride‑lowering profiles of olezarsen and plozasiran in FCS.

This segment frames the longstanding unmet clinical need in FCS and the limitations of traditional management strategies.

This video segment outlines the clinical features of familial chylomicronemia syndrome and introduces the emerging role of novel triglyceride-lowering therapies.

Experts discuss groundbreaking innovations in cardiovascular disease prevention, highlighting personalized medicine and new therapies for effective treatment.

Engaging patients in their treatment journey enhances adherence to therapies, ultimately improving health outcomes and managing cholesterol effectively.

Explore the barriers to PCSK9 inhibitors, their underuse, and how addressing misconceptions can enhance patient outcomes in cholesterol management.

Experts discuss evolving strategies in atherosclerosis prevention, emphasizing early intervention and the importance of cholesterol monitoring for better patient outcomes.

Experts discuss innovative strategies for managing statin-intolerant patients, highlighting new therapies and the importance of individualized care.

Experts discuss innovative strategies for managing statin-intolerant patients, highlighting new therapies and the importance of individualized care.

Healthcare professionals discuss strategies for effectively lowering LDL cholesterol in patients post-cardiac events, emphasizing early intervention and tailored therapies.

Healthcare professionals explore effective strategies for LDL cholesterol management, emphasizing patient involvement and innovative therapies for optimal outcomes.

A groundbreaking trial reveals the effectiveness of aggressive LDL lowering in high-risk patients, showcasing significant improvements in cholesterol management.